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ABSTRACT: 
 
One of the strategies in prevention or treatment of obesity is altering metabolism of lipids by 
inhibition of dietary fat absorption. The extracts obtained with methanol, water and 
methanol:water (1:1) from 21 mushroom species were screened as potential sources of pancreatic 
lipase (PL) inhibitors using a standardized in vitro test. Lepiota procera methanol:water (1:1) 
extracts showed the highest inhibition activity closely followed by Grifola frondosa, Pleurotus 
eryngii and Lyophyllum shimeji. Other mushroom strains such as Morcella conica, Marasmius 
oreades, Lentinula edodes, Amanita ponderosa and Boletus edulis also showed a certain 
inhibitory activity. However, when the PL inhibitory activity was evaluated using an in vitro 
digestion model mimicking gut conditions, none of the selected mushroom extracts were able to 
inhibit PL activity. On the contrary, stimulation of the lipase activity levels was observed and it 
was not due to endogenous mushroom lipases activities.  
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Introduction 
 
Obesity is the sixth most important risk factor contributing to the overall burden of disease 
worldwide reaching the category of epidemic. Nowadays, pharmacotherapy arises as useful tools 
to approach obesity. So far, there are three major drug options for the long-term treatment of 
obesity: orlistat (a gastric and lipase inhibitor), sibutramine (a monoamine reuptake inhibitor) and 
rimonabant (an endocannabinoid receptor blocker) (Padwal & Majumdar, 2007). However, obese 
and specially overweighed population is reluctant to assume obesity as a medical problem and, 
before turning to a health professional, starts his/her own therapy by using special foods, such as 
reduced fat content (light) products and nutritional supplements (including herbal extracts) and 
more often, diets without scientific evidence. 
Therefore, foods containing active principles with clear metabolic targets and scientific evidence 
of their activity may help in the self-fight against obesity, reaching to a higher number of 
individuals and in an earlier stage of their own obesity. A wide range of natural products 
(including crude extracts) mainly obtained from plants have been reported as effective pancreatic 
lipase (PL) inhibitors. For instance, berry polyphenols (McDougall et al., 2009), triterpenes from 
Sapindus sp (Morikawa et al., 2009), monoterpenes from Monarda punctata (Yamada et al., 
2010), abietanes from Salvia sp (Ninomiya et al., 2004) and more than 70 plant extracts (Sharma 
et al., 2005) showed PL inhibitory activity. The list of compounds and sources could be further 
extended with the findings of Birari & Bhutani (2007) and Slanc et al., (2004). The latter 
publication pointed fungi as a potential new source of PL inhibitors since within 60 edible and 
non-edible fungi species, PL inhibitory activities were found ranging from 1% till 97% 
depending on the specie considered.  
Only a few interesting PL inhibitors were isolated from edible fungi, two of them were β-lactones 
with unusual configurations named percyquinin (obtained from Stereum complicatum) and 
vibralactone (Boreostereum vibrans) with similar IC50 (0.4 µg/mL) (Liu et al., 2006; Birari & 
Bhutani 2007). For a few mushroom species, the observed activities were also effective in vivo 
according to the results obtained with animal models. Ahn et al., (2007) reported the antiobesity 
effects of Isaria sinclairii fruiting bodies and Mizutani et al., (2010) demonstrated the PL 
inhibitory activity of water extracts (polysaccharide-rich fraction) obtained from Pleurotus 
eryngii fruiting bodies.  
However, most of the former results were obtained from biochemical tests and no further studies 
to evaluate them under gut conditions were carried out. Positive scientific results in dead end may 
be mislead and produce misuse. For instance, a published scientific evidence of lipase inhibitory 
activity in some raw foodstuff or an herb does not mean that will have effect on fat absorption but 
can be interpreted like that, and wrongly used for that purpose. 
Thus, in this work the PL inhibitory activities of several extracts obtained from edible 
mushrooms were determined using a fast and standardized method and compared to the PL 
inhibitory activities obtained using an in vitro digestion model simulating the conditions in which 
the human PL would be involved in order to confirm or reject, in a step ahead, their lipase 
inhibitory capacity before animal testing.   
 
Materials and Methods 
 
Biological material  
Mushroom species used in this investigation were Lentinula edodes S. (Berkeley), Cantharellus 
cibarius (Fr.), Lactarius deliciosus (Fr.), Boletus edulis (Bull. Ex Fr.), Pleurotus ostreatus 
(Jacq.Ex Fr.) Kummer, Agaricus bisporus L. (Imbach), Amanita caesarea (Scop. Ex Fri.) Pers. 
Ex Schw.,  Morchella esculenta (Pers Ex Amans), Agaricus blazei Murill ss. (Heinem), Grifola 
frondosa (Dicks.) Gray, Ganoderma lucidum (Curtis) P.Karst., Flammulina velutipes (Curt. Ex 
Fr.) Singer, Pleurotus eryngii (D.C. Ex Fr.) Quel, Lyophyllum Shimeji (Kawam.), Morchella 
conica (Pers.), Agrocybe aegerita (Briganti) Singer, Auricularia judae (Bull. Ex St.Amans) 
Berck, Amanita ponderosa Malençon & R. Heim, Craterellus cornucopioides (L. Ex Fr.) Pers, 
Marasmius oreades (Bolt. Ex Fr.) Fr. and Lepiota procera (Scop. Ex Fr.) Singer.  Fruiting bodies 
were purchased from the local market in Madrid, Spain. Refined Sunflower oil, milk powder, 
walnut, dehydrated Cereals, dried banana were also obtained from local markets. All the 
experiments were performed using the same bottle, box or lotus. 
 Reagents 
Pancreatine (P-1750), lecithin, bile salts, maleic acid, 2,3-Dimercapto-1-propanol tributyrate 
(BALB), sodium dodecyl sulfate, 5,5´-Dithiobis (2-nitrobenzoic acid) (DTNB), D-mannitol, 
phenylmethylsulfonyl fluoride (PMSF) were procured from Sigma-Aldrich Co. Steinheim, 
Germany. Orlistat was purchased from Glaxo Group Limited, Middlesex, UK. All other reagents 
and solvents were used of analytical grade.  
Sample preparation 
Dried fruiting bodies dehydrated as described in Ramírez-Anguiano et al., (2007). The fruiting 
bodies were ground into fine powder using liquid nitrogen in a mortar. The mushroom powders 
(10 mg) were mixed with 1 mL of absolute methanol, a mixture methanol: water (1:1) or water, 
shacked on a Vortex (Heidolph Reax top, Germany) during 3 min and centrifuged (10000 rpm 2 
min) in a mini Centrifuge (Eppendorf, Minispin, Germany). The supernatants were screened as 
source of pancreatic lipase inhibitors. 
Pancreatic lipase activity using an standardized lipase assay kit  
Pancreatic lipase activity in the presence of mushroom extracts was measured using a 
QuantiChromTM Lipase assay kit (DLPS 100) from BioAssay Systems (Hayward, USA). A 
pancreatic lipase solution was prepared by mixing 19µg porcine pancreatin with 1 ml 50mM 
Trizma-maleate pH 7.5 and it was used as a lipase source. Mushroom supernatants (10 µl) were 
mixed with 40 µl of the pancreatic solution and 100 µl of a mixture including 5 mg DTNB, 8 µl 
BALB in ethanol and 100 µl tris(hydroxymethyl)aminoethane buffer pH 8.5 in a clear flat bottom 
96-well plate according to the user´s manual. Absorbance increase during 20 min at 412 nm and 
37ºC was recorded using a microplate reader (Tecan Group Lt, Switzerland). Lipase activity was 
expressed as indicated by the user´s manual. An Orlistat solution (0.75mg/mL) was also applied 
(10 µl) and used as a positive inhibitor control. 
Pancreatic lipase activity using an in vitro digestion model  
The samples (different concentrations of mushroom extracts with/without 1 g sunflower oil) were 
submitted to an in vitro intestinal digestion model carried out following the method described by 
Martín et al., (2010). The samples were mixed with 54 mL of 50mM Trizma-maleate buffer pH 
7.5 in a titrator device (Titrino plus Metrohm 877, Switzerland) maintaining temperature (37ºC), 
stirring and pH (7.5) constant for 120 min. Simulation of intestinal digestion was started by 
addition of 5mM CaCl2, 150 mM NaCl, and 6 mL of a pancreatin solution (1000 IUB/mL, 11.8 
mM bile salts and 1.3mM lecithin in the Trizma-maleate buffer). Every 30 minutes (including 
time 0 immediately after the mixture of the mushroom sample with the pancreatic mixture), 100 
µl of the digestion suspension were withdrawn, diluted with 1.8 ml 50 mM trizma-maleate buffer 
pH 7.5 and assayed for lipase activity (50 µl) according to the procedure of Furukawa et al., 
(1982). Briefly, diluted solutions were mixed with 1 ml of 0.3 mM DTNB and 20 µl PMSF. The 
mixture was incubated at 37oC for 5 min. Afterwards, 100 µl of a BALB solution (20 mM BALB 
and 20 mM SDS in ethanol) were added and incubated at 37oC for 30 min. The reaction was 
stopped by adding 2 ml acetone. Concomitantly, a zero sample of each assay was prepared as 
above described but with no substrate addition. Absorbance increase at 412 nm was recorded 
using a spectrophotometer (Evolution 600 Thermoscintific, England).  In vitro digestions of 
mushroom extracts were also carried out as before described but without lecithin and bile salts 
and the effect of these compounds was also evaluated on the test performance. Orlistat (1.48 
mg/g oil or 10 mg/ml depending on the type of experiment) was used as a positive inhibitor 
control. 
Mushrooms lipase activities  
Mushroom powders (10 mg/mL) were mixed with methanol:water (1:1) and diluted in buffer as 
described from samples obtained from the in vitro digestion model. Obtained mixtures (50 µl) 
were directly mixed with all the reagents to measure their lipase activity using the protocol 
described above by Furukawa et al., (1982) except for the pancreatin addition in order to evaluate 
the potential residual lipase activity that might occur due to endogenous mushroom lipases. 
Results and Discussion 
Screening of pancreatic lipase inhibitory activity  
Several extracts were obtained from mushroom fruiting bodies using methanol, methanol:water 
(1:1) and water as solvents (eight different concentrations ranging from 666 to 5.2 µg/mL) 
screened for pancreatic lipase (PL) inhibitory activity using an standardized lipase assay kit and a 
pancreatin solution.  
Extract concentrations lower than 166 µg/mL (corresponding to an enzyme:inhibitor ratio of 1:9 
in the final reaction volume) showed no PL inhibitory activity and the percentage of inhibition 
observed for these or higher concentrations was strain and solvent dependent. None of the water 
extracts showed significant PL inhibitory activities compared to controls. The highest inhibitory 
values were found on the methanol:water extracts except for Marasmius oreades (Table 1) and 
Morchella conica showing higher inhibition on their methanol than methanol:water (1:1) extracts 
(respect. 19.4% and 15.5%). Thus, results were in concordance with those of Slanc et al., (2004) 
pointing methanol:water as the best solvent mixture to extract PL inhibitors.  
The methanol:water (1:1) extracts obtained from the 21 selected mushroom strains were screened 
using the in vitro lipase assay kit for PL inhibitory capacities (Table 2) and many of them lacked 
inhibitory capacity or it was very low. However, Boletus edulis, Amanita ponderosa, Lentinula 
edodes, M. oredades, M. conica, Lyophyllum shimeji, P. eryngii and Grifola frondosa showed 
between 10% to 20% and Lepiota procera a PL inhibitory activity equivalent to the 25% of the 
selected orlistat concentration.  
Although, the PL inhibitory activities found in the latter species were four or five folds lower 
than the selected orlistat concentration (0.75 mg/mL) results might be of high interest. In fact, a 
foodstuff with a quarter of the orlistat activity could be recommended by nutritionists as part of a 
diet to lose weight. Therefore, the same mushroom extracts were tested under simulated gut 
conditions. 
Effect of in vitro digestion on the PL inhibitory activity of mushroom extracts 
In order to evaluate whether the mushroom extracts that showed positive PL inhibitory activity 
would still be able to carry out their potential effect on pancreatic lipase during human digestion, 
mushroom extracts were mixed with a fatty food matrix such as oil and submitted to an in vitro 
digestion model mimicking the intestinal digestion. 
The pancreatic lipase activity was monitorized in an in vitro digestion model during 2h using a 
sunflower oil digestion as control (Figure 1). As expected, the lipase activity levels showed a 
constant value of approx. 400 IUB/mL during the selected digestion period and conditions. The 
increasing volume of NaOH added into the digestion vessel by the tritiation device during the 
digestion indicated that the pancreatic lipases were degrading the oil triacylglycerides and 
releasing free fatty acids (provoking a reduction of pH that was compensated by the NaOH) 
(Martín et al., 2010). Under the selected in vitro conditions, the lipase reactions followed a 
hyperbolic curve needing approximately one hour to liberate most of the fatty acids although, a 
slight degradation was still observed until 2h digestion. This effect could correspond to the Ca2+ 
extinction in the media needed for the proper lipase activity (Porter et al., 2007). When the same 
digestion was performed in the presence of orlistat (1.48mg/g oil), activity was reduced by 
approx. 6 folds during the complete digestion time. However, when the oil was mixed with 
mushroom extracts of G. frondosa (51 mg/g oil dw), M. oreades (91 mg/g), and L. Procera (189 
mg/g) and submitted to in vitro digestion during 2 hr no inhibitory effect similar to orlistat was 
observed. A slightly but significantly lower PL activity was noticed at the beginning of the 
digestion when the samples containing the M. oreades and L. procera extracts were analyzed. 
However, as the digestion proceeded, in the samples containing M. oreades extracts, after 1h PL 
activity reached values similar to control and in those samples containing L. procera (applied in 
higher concentration) the PL activity values increased up to levels even higher than control. Thus, 
the PL inhibitory capacity detected for some mushroom species using the lipase activity kit might 
not have significant relevance when the lipase assay is performed simulating the digestion 
conditions in which pancreatic lipase might be involved in vivo. Therefore, the PL inhibitory 
capacity of all the selected mushroom strains was measured again but adding the mushroom 
extracts into a pancreatic lipase solution simulating the in vitro digestion conditions.  
Screening for pancreatic lipase inhibitors under simulated digestion conditions 
The methanol:water extracts of the selected edible mushrooms were screened again against 
pancreatic lipase activity but maintaining the in vitro digestion conditions and adjusting the 
inhibitor concentrations to similar conditions than those of the kit (enzyme:inhibitor ratio 1:8 in 
the final reaction volume).   
Results differed from those obtained when the enzymatic assay was performed using the lipase 
standardized kit (Table 2). Only Pleurotus eryngii extract showed an almost insignificant PL 
inhibitory activity under the simulated gut conditions, being lower than 7% of the orlistat 
inhibitory capacity. Those methanol:water extracts that showed PL inhibitory activity using the in 
vitro biochemical kit did not show activity when assayed simulating the gut conditions. Wise to 
mention was the fact that many of the mushroom species showed higher lipase activity than the 
negative control (methanol: water (1:1) solution instead of the extract).  
Since the obtained results appeared so different than those obtained using the standardized lipase 
assay and because practically none of the prepared mushroom extracts seemed to contain PL 
inhibitors, extractions with other solvents were assessed again. Therefore, some mushroom 
extracts were obtained using 100% methanol or water as a second attempt to screen for PL 
inhibitors under simulated digestion conditions (Table 3). Also in this case, none of the samples 
showed any interesting PL inhibitory activity except for orlistat and P. eryngii methanol extracts 
(with an almost insignificant inhibition) and on the contrary, some of the mushroom extracts 
showed lipase activity values higher than their control including only water, methanol or a 
methanol:water (1:1) mixture. Moreover, if the extracts were applied doubling the concentration, 
as it was tested for M. conica methanol extracts, P. eryngii water extracts and G. lucidum 
methanol:water extracts, the lipase activity was increasing and not decreasing as it would have 
been expected if the extracts would have contained any inhibitory compound. After the above 
described results it could be concluded that none of the tested mushroom extracts contained 
compounds in sufficient quantities able to reduce the pancreatic lipase activity under the 
simulated gut conditions. 
However, still remains unexplained the reason for increasing PL values in the presence of some 
of the mushroom extracts. Thus, further studies were carried out in order to clarify this 
unexpected behavior. The pancreatic lipase source used to carry out this experiments was not an 
isolated enzyme but a porcine pancreas extract (including co-lipases and other enzymes) so it 
could be hypothesized that the presence of lipids, lipid-related or lipidic fractions from the 
mushroom extracts might activate, induce or enhance the lipase activity as it was described for 
compounds such as triacylglicerides, etc. (Porter et al., 2007) since the presence or absence of 
lecithin nor bile salt in the reaction medium influenced the PL activity values. Another possible 
explanation could be that the mushroom extracts might also contain endogenous lipases that 
might interfere with the reaction since fungal lipases have been previously described in some of 
the mushroom strains (Krügener et al., 2009).  
Thus, in order to further clarify the obtained results, the lipase activity of the mushroom extracts 
was measured and on the other hand, the pancreatic lipase assay mimicking the gut conditions 
was carried out in the presence of various food extracts and pure compounds with different lipidic 
composition. 
Methanol:water mushroom extracts were submitted to the lipase activity test under similar 
conditions than the in vitro digestion assay but without pancreatin addition. Thus, the observed 
activity could be only due to fungal lipases. As expected, results indicated that none of the 
selected strains showed significant lipase activity compared to the control with pancreatin (Table 
4) since the extraction solvent contained methanol and mushroom enzymes (mainly 
exoenzymes), although they can tolerate certain level of organic solvents, they exert their activity 
using water or specific buffer. Moreover, their lipase activity values did not correlate with the 
mushroom species which showed higher PL activity (in Table 2). Thus, the endogenous 
mushroom lipases were not the responsible for the increasing of lipase activity observed during in 
vitro digestion of the extracts. 
Sucrose, starch or dehydrated wheat (as breakfast cereals) was selected as example of 
carbohydrates-rich foodstuff. Serum bovine albumin (BSA) and defatted milk powder were 
selected as protein rich sources. When the methanol:water (1:1) extracts were obtained from 
these poor lipid-containing samples and assayed for lipase activity no significant differences in 
PL activity levels were observed compared to control (Table 5). However, when dehydrated 
banana and walnut extracts (selected as example of lipid-containing foodstuff) were tested, 
pancreatic lipase activities increased up to similar levels than those observed for some of the 
mushroom extracts (for instance M. conica). Moreover, when the powdered walnut or M. conica 
were mixed with a drop of sunflower oil (285mg/g) an even higher PL activity increase was 
observed suggesting that the enhancing of lipase activity is related to lipidic compounds. 
Edible mushrooms are highly recommended in diets for overweighed people particularly because 
they are considered as low-fat food (Kalač, 2009). Thus, a minor compound or group of 
compounds (of lipidic nature) could be the responsible for the stimulation of PL activity, perhaps 
sterols since cholesterol was described as compound able to mediate pancreatic lipase activity 
(Ros, 2000). Mushroom fruiting bodies contain ergosterol as the major sterol constituent of the 
fungal membrane and it was present in the selected mushroom strains in a concentration range 
between 5.69 to 0.69 mg/g (Gil-Ramirez et al., 2011). However, when the ergosterol levels were 
plotted toward PL activity measured by the in vitro digestion model no correlation was found 
leaving the responsible compound / group of compounds still unidentified. Other compounds 
such as saponins have been described as stimulating compounds of pancreatic lipases, however, 
edible mushrooms do not contain this type of compounds (Sroka et al., 1997). 
Conclusions 
Thus, it could be concluded that, although some mushroom extracts showed PL inhibitory 
activity in an in vitro test, under the in vitro digestion model utilized mimicking the intestinal 
human conditions, the selected mushroom species were not able to effectively inhibit the 
pancreatic lipase when mixed with a food matrix as sunflower oil or directly applied as 
mushroom extract. These results strengthen the need of more detailed studies before concluding 
the ability of natural extracts to perform certain biological activities by using only in vitro 
biochemical tests. Therefore, the use of mushroom extracts i.e. as ingredient to formulate 
functional foods able to act as orlistat is, in any case, of limited significance. On the other hand, 
further studies are, at the present, being conducted to clarify the stimulation of PL activity 
observed.  
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Table 1, Pancreatic lipase activity (U/L) using the standardized lipase activity kit of Marasmius 
oreades (166 mg/mL) methanol, methanol:water (1:1) and water extracts. 
Control Extract 
Water 252.14 ± 3.34 244.25 ± 6.08  
Methanol: water (1:1) 255.68 ± 0.15  229.22 ± 2.84  
Methanol 294.38 ± 56.76  212.83 ± 7.54  
ORL 44.13 ± 0.73  
 
 
  
Table 2, Pancreatic lipase (PL) activity in the presence of methanol:water  (1:1) extracts obtained 
from several fruiting bodies. The PL activity was measured by two different methods. Enzymatic 
activity is expressed as percentage compared to a control sample including only a methanol:water  
(1:1) solution. 
 
Mushroom species 
PL activity assessed  
using an enzymatic kit 
(%) 
PL activity assessed 
using an 
in vitro digestion model 
(%) 
 
Cantharellus cibarius 106.89 ± 12.03 124.62 ± 1.62  
Lactarius deliciosus 106.55 ± 0.96 123.21 ± 17.32  
Amanita Caesarea 105.08 ± 0.80  122.98 ± 7.03  
Flammulina velutipes 103.01 ± 6.55  165.47 ± 11.24  
Morchella Esculenta 100.22 ± 0.53  131.12 ± 8.49  
Ganoderma lucidum 100.61 ± 0.80  221.61 ± 9.49  
Agrocybe aegerita 96.16 ± 4.00  121.56 ± 6.67  
Agaricus blazei 96.13 ± 4.58  99.36 ± 12.88  
Craterellus cornucopioides 95.75 ± 0.96  181.04 ± 9.83  
Auricularia judae 93.42 ± 1.28  104.97 ± 6.31  
Agaricus bisporus 93.27 ± 1.01  127.42 ± 5.95  
Pleurotus ostreatus 92.53 ± 2.92  123.98 ± 0.47  
Boletus edulis 87.35 ± 2.74  106.01 ± 16.45  
Amanita ponderosa 86,18 ± 2.74  167.30 ± 24.35  
Lentinula edodes 86.10 ± 3.77  165.71 ± 10.19  
Marasmius oreades 85.81 ± 1.06  159.19 ± 9.81  
Morcella conica 84.46 ± 0.00   96.21 ± 20.70  
Lyophyllum shimeji 83.14 ± 1.01  220.87 ± 14.41  
Pleurotus eryngii 82.69 ± 1.12  95.44 ± 0.94  
Grifola frondosa 82.46 ± 4.00  118.22 ± 19.25  
Lepiota procera 79.07 ± 0.29  152.42 ± 0.23  
Orlistat 16.45 ± 1.33  33.09 ± 15.25  
 
 
 
Table 3, Pancreatic lipase activity (IUB/mL) in the presence of several mushroom extracts (using 
water, methanol and methanol:water (1:1)) simulating the in vitro digestion conditions.   
Mush.extracts Water Methanol:water (1:1) Methanol 
Control 961.38 ± 99.79 1076.04 ± 23.11 1253.91 ± 45.74  
G. lucidum 979.02 ± 112.26  1362.69 ± 130.97  1772.82 ± 128.90  
M. conica 1290.66 ± 66.52  1858.08 ± 274.41  1571.43 ± 68.60  
P. eryngii 1121.83 ± 174.13  997.89 ± 64.11  892.61 ± 158.11  
L. edodes 1646.40 ± 332.62  1166.89 ± 26.19  1073.69 ± 205.81  
ORL 247.62 ± 48.39  161.41 ± 71.59  155.11 ± 5.27  
 
 
  
 Table 4, Endogenous lipase activity determined in several mushroom extracts using the in vitro 
digestion conditions but in absence of pancreatin 
Mushroom species PL (IUB/mL) 
 
Control (MeOH:water 1:1) 126.4 ± 8.3 
Lyophillum shimeji 132.3 ± 8.3  
Craterellus cornucopioides 117.6 ± 12.5  
Pleurotus eryngii 111.7 ± 8.3  
Agaricus blazeii 123.5 ± 8.3  
Amanita caesarea 147.0 ± 8.3  
Morchella conica 113.2 ± 10.4 
Control (with pancreatine) 1123.1 ± 198.4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5, Pancreatic lipase activity of some lipidic and non-lipidic food matrices and pure 
compounds using the simulated in vitro digestion conditions. 
Food extracts PL activity (IUB/mL) 
Control  1123.08 ± 198.42 
Sugar 1261.26 ± 41.58 
Starch 1149.54 ± 158.00  
BSA 1145.13 ± 172.55 
Dehydrated wheat (Cereal) 1056.93 ± 81.08  
Defatted milk powder 1331.08 ± 76.90  
Dehydrated banana 1718.59 ± 2.08  
Walnut 1822.80 ± 49.90  
Walnut with oil 2335.83 ± 76.90 
Morchella conica 1858.08 ± 274.41  
Morchella conica with oil 2475.48 ± 241.15  
ORL 155.11 ± 5.27  
 
 
 
  
Figure legends  
 
Figure 1, Pancreatic lipase activity during an in vitro digestion model of mushroom extracts 
mixed with sunflower oil. Digestion of sunflower oil was used as not inhibited control and 
orlistat digestion as inhibited control. 
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